Crowdonomics
All companies
PsiloThera, Inc. logo

PsiloThera, Inc.

Operating

Biotech · Henderson, WY · Founded 2020

Psychedelic Healthcare Innovation

Post-money valuation ⓘ
$50.2M
As of Mar 2022 · from Reg CF Offering (2021) · pre-money + amount raised, not a traded price
Total raised
$172,586
Across 1 round since 2021
Latest share price
$5.00
Reg CF · Common Stock · Jul 2021 offering price

Financials

FY2019–FY2022 · from SEC filings · hover any figure for its source
$0
2019
$0
2020
$0
$152K
2021
$0
$57K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019 audited
FY2020 audited
FY2021 unaudited
FY2022 unaudited
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
$0
$0
$152,250
$56,538
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$0
$0
$2,293
$3,661
Accounts receivable
$0
$0
$0
$0
Total assets
$0
$0
$2,293
$3,661
Short-term debt
$0
$0
$0
$0
Long-term debt
$0
$0
$48,100
$82,100
Total liabilities
$0
$0
$48,100
$82,100
Other
Headcount
—
10
10
8

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$50.0M
pre-money
Reg CF · Common · Jul 2021

Blue bars are the pre-money valuation the company stated for a priced round.

Cap table

Share counts as of Dec 31, 2020
ClassOutstandingVotes / shareShare of totalLast price
Common Stock300,000—100.0%$5.00Jul 2021

Principal holders% as the filing states it, Apr 28, 2022

  • Charles John Atanasio, Jr.1,600,000 Common Stock16.0%of company
  • Holly Scott1,600,000 Common Stock16.0%of company

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $172.6K / $5MInvestors 164Post-money $50.2M

Team

15 people
"Chaplain Chuck" AtanasioFounder
Director of Research, Psychologist, Retired Army Major, Chaplain & Behavioral Specialist

Chaplain Chuck will spearhead our clinical approach and shall develop our Veteran & Civilian Psilocybin Therapeutic Studies and Programs & Suicide Prevention Programs. Chaplain Chuck trained hundreds of military personnel once a year in suicide prevention for 16 years. He has also been Certified to Train First Responders on suicide intervention. An Iraqi Combat Vet, he has served 25 years in the military as an Army Chaplain and as a Behavioral Science Specialist. Chuck has a MSW Degree in Social Work from Marywood University and a MS in Experimental Psychology from Purdue University and a BA in Psychology from Seton Hall University. Notable Service of Achievement and Invaluable Experience: Awarded Bronze Star & GWOT Expeditionary Medal for Military Service, 2003-2004. GWOT=Global War on Terrorism. Operation Iraqi Freedom; Awarded General Petraeus Excellence in Combat Coin. Chaplain Chuck has provided compassionate spiritual needs assessments, care & counseling to increase the resiliency of hundreds of individuals, couples and families in: burn wards, combat operations, in-patient psychiatric wards critical incidents, emergency rooms, funeral homes, hospice, hospitals, memorials, military deployments and exercises, nursing homes, orphanages, prisons, relationship enhancement retreats and work office settings.

Adam BellFounder
Creative Director- Web Design & Strategy

Adam Bell has been designing and developing website projects for twenty five years. He has worked on a variety of projects in the world of e-commerce and entertainment. Current projects are with Cafe du Monde, Tattoo Tequila, Skull + Monarch Auctions + Galleries and PowerAnimal Pet Foods. In the past he’s worked with the likes of Ovation TV, Amblin Partners, Tender Greens and the Ford Motor Company among many others. He’s worked with everyone from small startups to multi-national corporations. Adam is going to help spearhead the development of a groundbreaking e-Mental Health initiative that will provide relief from suffering for millions a people.

Anthony AmatucciFounder
Legislative Analyst

Anthony shall act as our legislative analyst and activist to promote the Legalization of Psilocybin for use in therapeutic settings. Anthony has several years of experience working for former U.S. Rep. Leonard Lance of NJ and Senator Tom Kean and his issue coverage and focus was Healthcare, Infrastructure and Taxes.

Anthony BaldassariFounder
Behavioral Analyst

Anthony shall we be part of our team that shall be working with high risk patients. Anthony recently Earned his MA in Behavioral Analysis from Florida Institute of Technology and previously earned his BA from the University of Colorado in Neuroscience and Psychology. Anthony has worked at RBT since 2017 and has worked with individuals of all ages with a wide range neurodevelopment disorders. His research Interest include the use of ABA with individuals with dramatic brain injuries and individuals with co-morbid mental health and neurodevelopment disorders diagnosis.

Dan VoslerFounder
Director of IT

Daniel is Linux Systems Engineer and has been recently been working in the academic research space with some of the best computer science programs in the world. Daniel believes we have a core responsibility to steward our resources to benefit humanity; especially to those in need of care.

Ed GalisewskiFounder
Spiritual Advisor

Ed Galisewski has spent his entire career working in the field of Pharmaceutical sales. 29 years as a Virology/HIV Sales rep for Abbvie selling cutting edge Protease Inhibitors and now the last 5 years as the Regional Account Manager for Walgreens Specialty Pharmacy division covering several states. Ed has also served for 35 years as a Lay Pastor for several large suburban churches as a Men’s Ministry Director. His passion has always been about getting men together to talk freely about their life struggles and help them wrestle with their questions about faith. Ed is the author of two books that explore the concept of why people walk away from religion. “A Simpler Faith” and “Simplifying Religion” are his two book titles. His underlying goal for both books is to bring people back to faith in a world where Religion seems to be pushing people away form it.

Glen Biondi, Esq.Founder
Legal Advisor

Mr. Biondi obtained his Law Degree from Thomas Jefferson School of Law in San Diego, California and has been practicing law in California since 2000. Mr. Biondi shall advise Psilothera on wide array of Corporate legal matters. Prior to his Law Career he held positions in the Financial Services Industries and also he owned his own Contracting company. However, after undergoing a double-lung transplant in 1993, he was forced to change careers and eventually leading Glen to his career in Law.

Holly ScottFounder
Director of Fungi Grow & Cultivation

Holly is the “Mushroom Queen” and will lead our grow operations and has extensive experience in this area of specialization. Holly has curated a portfolio of (20) Psilocybe species spores to launch an extensive Psilocybe grow operation.

Howard "Mystro' StromanFounder
Business Development & Strategy

"Mystro” shall focus on opportunities to drive growth via strategic partners and alliances. Professionally Mystro is a. Music & Entertainment Industry Executive and iconic Vegas Music Director & Performer. He is a serial entrepreneur with business interests in the areas of Music Production, Internet + Technology, Craft Spirits, Cannabis, CBD & Quantum Technology.

Show 6 more people
Jacquelyn Wright-MinogueFounder
Advisor- Clinical Trials & Founder

Jacquelyn Wright-Minogue, MS, PMP has over 30 years of pharmaceutical industry experience. Jackie first joined Schering-Plough in the pathology area. She then moved onto basic research and clinical research in several therapeutic areas such as pathology, virology, allergy and immunology, oncology and rare diseases. Her cloning, RT-PCR and DNA sequencing knowledge and skills led her to an adjust professor teaching position at a Kean University where she taught master level courses in DNA sequencing. Feeling the need to get closer to the patient experience after 20 years in basic scientific research, Jackie leaves Schering-Plough/Merck, and moves onto Novartis to work on oncology trials. Working on clinical trials for medulloblastoma in children and basal cell carcinoma. The drug was approved by the FDA as sonidegib for locally advanced basal cell carcinoma. From big pharma, Jackie moved onto a small biotech company called Amicus Therapeutics where she quickly advanced to her current role as Sr. Director of Clinical Operations. Jackie helped spearhead and enrolled the largest ever trial in Pompe Disease in record time, keeping patients on study during a global pandemic. It is her life mission to get medication to those in need. During the pandemic more people are suffering from mental illness than ever before. Jackie believes that this unmet medical need could benefit from a healthier, natural option with less side effects than traditional medicine.

Jan RydfordsFounder
Doctor- Medical Advisor

Dr. Rydfors received his Medical degree and specialization training from Stanford University Medical Center where he is an Adjunct Clinical Professor. Dr Rydfors has extensive experience in high risk Obstetrics, advanced fertility treatment and treatment of recurrent miscarriages. Over the last 30 years, Dr Rydfors has developed a successful multidisciplinary program to prevent recurrent miscarriages which attracts patients from all over the US. His interests include also autism prevention in pregnancy. He is the initial creator and current Co-Author of the popular “Handbook in Obstetrics, Gynecology and Infertility,” now in its sixth edition, the main handbook used by all Obstetricians and Gynecologists in training in the US. He was the founder of OBOnTheGo and EmbraceHerHealth which made the most complete medical grade pregnancy Mobile Apps when they came out and currently is a co-founder of EverDoc where powerful AI and Machine Learning is being used to optimize medical care. He is the Chief Medical Advisor for the American Pregnancy Association and acts as a Medical Advisor for several Silicon Valley Companies. He is the recipient of the Compassionate Doctor, Marquis who’s who in the world and Patient’s Choice award.

John AtanasioFounder
CEO and Founder

John is a Visionary and Serial Entrepreneur with significant Executive Management experience. He is an Advocate for Psilocybin Decriminalization & Legalization and Testified in Support of Psilocybin Decriminalization at a Session of the State of Hawaii Legislature debating SB:38 on February 2021. John has a Successful track record of developing and working with next generation web based platforms & technologies for Healthcare & Medical Industries: Electronic Medical Record (EMR) Technologies, e-RX Technologies, Online Physician Platforms & Patient Wellness App.

Leif RydforsFounder
Patient Advocate - Spokesperson

Leif’s passion for healing stems from the challenges he faced during a life-long battle with debilitating depression and anxiety. His tenacity and desire for emotional relief led him to seek treatment. After reading about the cutting-edge research that was done in John’s Hopkins University and Imperial College in London his intrigue led him to action. His psilocybin treatment along with his spirituality has clearly shown him that we were put here on this planet to serve. His biggest desire is for global awakening and he feels compelled to help people navigate through the deep waters of true self-discovery. Leif is determined and compelled to offer the guidance of his experience to transcend the pain and suffering of others in need.

Michelle Pon TellFounder
Head Therapist-Advisor

Michelle Pon Tell, Head Therapist, LCSW, MA, CCTP Michelle is a Certified Clinical Trauma Professional, clinically trained in Somatic Experiencing, a method ideally suited to gently releasing the stress, anxiety, trauma and overwhelm trapped in one's body. This powerful modality allows clients to quickly resolve past emotional issues so they can move forward with a sense of joy and freedom. Her experiences working with Hospice, as well as providing intensive in-home therapy to families, has allowed Michelle the humbling privilege of walking with all types of individuals through some of life's most difficult circumstances. Whatever your situation, she is available to meet you where you are and help you get to where you want to be.

Spike HumerFounder
Business Development & Strategy

Spike Humer shall advise Psilothera in areas of Business Development and Strategy. Spike is widely-recognized as a thought-leader and world-renowned expert in leading and inspiring companies, organizations, and individuals to achieve more, have more, and be more. He’s been called the “mentor’s mentor” and is highly regarded as a master marketing strategist and performance acceleration expert. Spike serves as a trusted advisor and performance consultant to entrepreneurs and individuals from virtually every walk-of-life and in countless industries. He is an acclaimed author, speaker, thought-leader, and creator of “The 10 Day Turnaround Methodologies”, “Rapid Success Technologies”, and “The Overnight Entrepreneur” seminars, book, and workshop series.

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 2 of 5 annual reports (FY2021–FY2025)

164 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRApr 17, 20240001665160-24-000375
    EDGAR
  • Form C-ARApr 26, 20230001665160-23-000801
    EDGAR
  • Form C-ARApr 28, 20220001665160-22-001054
    EDGAR
  • Form C-UMar 23, 20220001665160-22-000509
    EDGAR
  • Form C/AJan 6, 20220001665160-22-000042
    EDGAR
  • Form CJul 22, 20210001665160-21-001294
    EDGAR
Source: ManualCIK 0001873480WYShare price $5.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.